Hold Rating for Avadel Pharmaceuticals Amidst Upcoming Acquisition and Market Complexities
I'm PortAI, I can summarize articles.
Andrew Tsai has assigned a Hold rating for Avadel Pharmaceuticals due to the upcoming acquisition by Alkermes, valued at up to $2.1 billion, expected to close in Q1 2026. This rating reflects the growth potential of Avadel's drug Lumryz, despite complexities from a legal settlement with Jazz Pharmaceuticals affecting sales until 2028. The anticipated development of a new salt-free version of Lumryz by 2028 also impacts the outlook. Tsai is a 5-star analyst with a 16.2% average return and a 57.64% success rate in the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments